01 / DESIGN
What was studied?
Model insulin compacts combined two permeation enhancers with excipients and underwent compression, release and accelerated-storage testing.
02 / FINDINGS
What did the researchers report?
The enhancers differed in manufacturing properties. Blended formulations showed different degradation and aggregation behavior from raw insulin under the tested storage conditions.
03 / LIMITS
How should it be interpreted?
Accelerated model testing does not determine a universal shelf life. Excipient effects are formulation-specific, and these results do not provide a preparation recipe for catalog products.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.